Chronic hepatitis C (CH-C) genotype 1: An independent, multicenter RCT comparing PEG-IFN ALFA-2B 12KD plus ribavirin (RBV) and IFN ALFA-2B plus (RBV) in naive patients
Savino Bruno(Humanitas University), G. Pinzello, Mario Camozzi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), V. Di Marco(University of Palermo), M. Vinci(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Danilo Di Bona(Istituto di Biomedicina e di Immunologia Molecolare Alberto Monroy), Mario U. Mondelli(University of Pavia), Maria Grazia Rumi(University of Milan), M. Colombo(University of Milan), Antonio Craxı̀(University of Palermo), Calogero Cammà(Department of Health)
Cited by 1
Related Papers
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661